Yahoo Finance • 5 months ago
BridgeBio Pharma, Inc. PALO ALTO, Calif., July 05, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, today announced th... Full story
Yahoo Finance • 6 months ago
BridgeBio Pharma, Inc. - Acoramidis treatment resulted in increased serum transthyretin (TTR) levels by Day 28 that were sustained and were correlated with a reduced risk of all-cause mortality (ACM), cardiovascular mortality (CVM), and c... Full story
Yahoo Finance • 8 months ago
BridgeBio Pharma, Inc. - In this exploratory substudy, treatment with acoramidis was associated with possible cardiac structural and functional improvement compared with placebo, with potential cardiac amyloid regression - The data demon... Full story
Yahoo Finance • 9 months ago
March 4 (Reuters) - BridgeBio Pharma has granted German drugmaker Bayer an exclusive license to commercialize its heart disease drug in Europe, the companies said on Monday. The experimental drug, acoramidis, is being developed as an oral... Full story
Yahoo Finance • 9 months ago
BridgeBio Pharma, Inc. - BridgeBio grants Bayer exclusive license to commercialize acoramidis as a treatment for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in Europe - BridgeBio to receive royalties according to a tiere... Full story
Yahoo Finance • 9 months ago
In this piece, we will take a look at the 14 best medical stocks to invest in according to hedge funds. If you want to skip our overview of the medical and healthcare industry, then you can take a look at the 5 Best Medical Stocks To Inves... Full story
Yahoo Finance • 10 months ago
BridgeBio Pharma, Inc. - The raise includes $500 million in cash from Blue Owl and CPP Investments in exchange for a 5% royalty on future global net sales of acoramidis - The raise also includes a $450 million credit facility from Blue O... Full story
Yahoo Finance • 10 months ago
In this article, we will take a detailed look at the16Best Mid-Cap Growth Stocks To Buy Now. For a quick overview of such stocks, read our article 5Best Mid-Cap Growth Stocks To Buy Now. Investors are hopeful that small- and mid-cap stock... Full story
Yahoo Finance • 11 months ago
BridgeBio Pharma, Inc. The United States Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for BBO-8520, a first-in-class orally bioavailable and potentially highly potent small molecule direct... Full story
Yahoo Finance • 11 months ago
In this article, we will take a look at 13 high growth healthcare stocks to buy. To skip our analysis of the recent market activity, you can go directly to see the 5 Best High Growth Healthcare Stocks to Buy. For the purpose of this artic... Full story
Yahoo Finance • last year
- As previously announced, the primary endpoint (a hierarchical analysis inclusive of all-cause mortality and frequency of cardiovascular-related hospitalization) was met (Win Ratio of 1.8) with a highly statistically significant p-value (... Full story
Yahoo Finance • last year
PALO ALTO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that additio... Full story
Yahoo Finance • last year
BridgeBio Pharma Inc (NASDAQ:BBIO) reported Q3 2023 revenue of $4.1 million, compared to $0.3 million in Q3 2022. The company ended Q3 2023 with $522 million in cash, cash equivalents, and short-term restricted cash. BBIO raised approximat... Full story
Yahoo Finance • last year
- Presented detailed positive results from the ATTRibute-CM Phase 3 study of acoramidis at the European Society of Cardiology (ESC) Congress, demonstrating that patients survived more and were hospitalized less than has been seen in other... Full story
Yahoo Finance • last year
PALO ALTO, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on Octo... Full story
Yahoo Finance • last year
- In our study, encaleret restored physiologic mineral homeostasis in 13 participants with ADH1, specifically correcting hypocalcemia and reducing hypercalciuria - Rapid and sustained impact of encaleret on mineral homeostasis was observe... Full story
Yahoo Finance • last year
- Early assessment of increased glycosylated ⍺DG levels at 3 months predicted subsequent ambulatory improvements at 9 months, supporting the use of glycosylated ⍺DG levels as a potential surrogate endpoint in LGDM2I/R9 - Long-term data fr... Full story
Yahoo Finance • last year
- $250 million financing led by Qatar Investment Authority (QIA) with significant participation from four of the largest investment management firms in the US - BridgeBio anticipates this raise, coupled with several less dilutive financin... Full story
Yahoo Finance • last year
- BridgeBio completed an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), and a scientific advice engagement with the European Union (EU) European Medicines Agency (EMA) - FDA and EMA alignment was reached on the a... Full story
Yahoo Finance • last year
- The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001); this primary endpoint result consistently favored acoramidis treatment across key subgroups, including across both variant and wi... Full story